<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195010</url>
  </required_header>
  <id_info>
    <org_study_id>9799</org_study_id>
    <secondary_id>NCI-2017-00864</secondary_id>
    <secondary_id>9799</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT03195010</nct_id>
  </id_info>
  <brief_title>Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia</brief_title>
  <official_title>Management of Venous Thromboembolic Events (VTE) in Patients With Hematologic Disorders and Treatment-Induced Thrombocytopenia: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial compares the safety of two different platelet transfusion
      &quot;thresholds&quot; among patients with blood cancer or treatment-induced thrombocytopenia whose
      condition requires anticoagulant medication (blood thinners) for blood clots. Giving
      relatively fewer platelet transfusions may reduce the side effects of frequent platelet
      transfusions without leading to undue bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine feasibility of a randomized controlled trial comparing two different platelet
      transfusion thresholds (50 x 10^9/L versus [vs] 30 x 10^9/L) in patients with treatment or
      malignancy-induced thrombocytopenia requiring therapeutic anticoagulation.

      SECONDARY OBJECTIVES:

      I. Progressive or new venous thromboembolic (VTE).

      II. Progressive or new arterial thromboembolism (ATE).

      III. Hemorrhagic events (World Health Organization [WHO] grade 2 or greater).

      IV. A composite of I, II and III.

      V. Major bleeds (WHO grade 3 or 4).

      VI. Number of platelet transfusions per patient during the study period.

      VII. Platelet transfusion related complications (including transfusion reactions,
      alloimmunization and volume overload).

      VIII. Degree to which platelet target thresholds are achieved.

      OUTLINE: Patients are randomized into 1 of 2 groups.

      GROUP I (Lower dose): Patients undergo platelet transfusion on all days when the morning
      platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet
      count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of
      transfusions.

      GROUP II (Higher dose): Patients undergo platelet transfusion on all days when the morning
      platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet
      count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of
      transfusions.

      After completion of study, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated because of slow recruitment and lack of funding support
  </why_stopped>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Actual">December 21, 2018</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eligible Patients Approached for the Study</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Approached for But Refusing Consent</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Reasons for ineligibility will be reported qualitatively in order to inform future studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Consenting to Enrollment</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Eligible</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Screened and Deemed Ineligible</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Reasons for ineligibility will be reported qualitatively in order to inform future studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Successfully Following Protocol</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will evaluate the number of patients successfully following protocol, defined as receiving transfusions 'on protocol' at the end of the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hemorrhagic Events (World Health Organization Grade 2 or Greater)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will evaluate the incidence of hemorrhagic events (World Health Organization grade 2 or greater).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeds (World Health Organization Grade 3 or 4)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will evaluate the major bleeds (World Health Organization grade 3 or 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Platelet Transfusions Per Patient During the Study Period</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Days on Which Subjects Are Transfused (or Transfusion Are Not Given)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The frequency with which transfusions are given despite a platelet count above the determined threshold will be documented, as will the frequency with which transfusions are not administered within 24 hours after a platelet count below the determined threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Transfusion Related Complications</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Total number of transfusion reactions, patients experiencing alloimmunization and volume overload will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive or New Arterial Thromboembolism</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will evaluate the progression or new arterial thromboembolism by either documented acute electrocardiographic changes compatible with myocardial injury and/or serum biochemical changes diagnostic of myocardial infarction, or documented imaging (computed tomography or magnetic resonance imaging) changes compatible with infarct due to embolism in the presence of a new neurological deficit, or imaging demonstrated intraluminal filling defects in an arterial distribution accompanied by symptoms of acute ischemia (acute onset pain, pallor, loss of pulses or other end-organ damage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive or New Venous Thromboembolic</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will evaluate the progressive or new venous thromboembolic. Will require imaging confirmation, defined as intraluminal filling defect(s) on contrast-enhanced computed tomography or incompressible venous segment(s) on ultrasonography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Hematologic and Lymphocytic Disorder</condition>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis</condition>
  <condition>T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Thrombocytopenia</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Group I (lower dose platelet transfusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (higher dose platelet transfusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Transfusion</intervention_name>
    <description>Undergo lower dose platelet transfusion</description>
    <arm_group_label>Group I (lower dose platelet transfusion)</arm_group_label>
    <other_name>Blood Platelet Transfusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Transfusion</intervention_name>
    <description>Undergo higher dose platelet transfusion</description>
    <arm_group_label>Group II (higher dose platelet transfusion)</arm_group_label>
    <other_name>Blood Platelet Transfusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with non-acute promyelocytic leukemia (APL) acute leukemia (acute myeloid
             leukemia [AML], acute lymphoblastic leukemia [ALL], biphenotypic leukemia) undergoing
             curative intent chemotherapy OR any patient undergoing allogeneic hematopoietic stem
             cell transplantation (HSCT) for a hematologic disorder (including acute leukemia as
             above, chronic myelogenous leukemia [CML], chronic lymphocytic leukemia [CLL],
             myelodysplastic syndrome [MDS], primary or secondary myelofibrosis, hypereosinophilic
             syndromes, plasma cell disorders, B-cell or T-cell lymphoma)

          -  Disease may be measurable or non-measurable

          -  Diagnosis of symptomatic venous thromboembolism requiring therapeutic-dose
             anticoagulation (unfractionated or low-molecular weight heparin or oral
             anticoagulants) throughout the period of hematopoietic recovery

          -  Anticipated platelet count =&lt; 50 x 10^9/L for &gt;= 5 days within 72 hours of enrollment

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Separate episode of VTE or arterial thrombosis within 3 months of enrollment

          -  Major bleed (WHO grade 3 or 4) within 6 months of enrollment

          -  Active bleeding (grade 2 or higher) at the time of enrollment

          -  History of intracranial bleeding at any time

          -  Disorders of hemostasis including von Willebrand disease, hemophilia, platelet
             function disorders

          -  Concomitant use of aspirin or non-steroidal anti-inflammatory drugs

          -  Evidence of disseminated intravascular anticoagulation (DIC) as determined by the
             patient's primary provider

          -  History of alloimmunization (defined as platelet refractoriness with panel reactive
             antibody [PRA] &gt; 25%) at the time of or prior to enrollment

          -  Uncontrolled or concurrent illness including, but not limited to, ongoing or active
             infection, unstable angina pectoris

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements

          -  Pregnant or able to become pregnant and unwilling to use two forms of birth control
             during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Garcia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <results_first_submitted>September 23, 2019</results_first_submitted>
  <results_first_submitted_qc>October 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2019</results_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03195010/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group I (Lower Dose Platelet Transfusion)</title>
          <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
        </group>
        <group group_id="P2">
          <title>Group II (Higher Dose Platelet Transfusion)</title>
          <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I (Lower Dose Platelet Transfusion)</title>
          <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
        </group>
        <group group_id="B2">
          <title>Group II (Higher Dose Platelet Transfusion)</title>
          <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="23" upper_limit="61"/>
                    <measurement group_id="B2" value="35" lower_limit="30" upper_limit="40"/>
                    <measurement group_id="B3" value="39" lower_limit="23" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eligible Patients Approached for the Study</title>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Approached Patients</title>
            <description>Eligible patients approached for participation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eligible Patients Approached for the Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Approached for But Refusing Consent</title>
        <description>Reasons for ineligibility will be reported qualitatively in order to inform future studies.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Approached Patients</title>
            <description>Eligible patients approached for participation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Approached for But Refusing Consent</title>
          <description>Reasons for ineligibility will be reported qualitatively in order to inform future studies.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Consenting to Enrollment</title>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Approached Patients</title>
            <description>Eligible patients approached for participation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Consenting to Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Eligible</title>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Screened Patients</title>
            <description>Patients screened for eligibility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Eligible</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Screened and Deemed Ineligible</title>
        <description>Reasons for ineligibility will be reported qualitatively in order to inform future studies.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Screened Patients</title>
            <description>Patients screened for eligibility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Screened and Deemed Ineligible</title>
          <description>Reasons for ineligibility will be reported qualitatively in order to inform future studies.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Successfully Following Protocol</title>
        <description>Will evaluate the number of patients successfully following protocol, defined as receiving transfusions 'on protocol' at the end of the study period.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Successfully Following Protocol</title>
          <description>Will evaluate the number of patients successfully following protocol, defined as receiving transfusions 'on protocol' at the end of the study period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hemorrhagic Events (World Health Organization Grade 2 or Greater)</title>
        <description>Will evaluate the incidence of hemorrhagic events (World Health Organization grade 2 or greater).</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hemorrhagic Events (World Health Organization Grade 2 or Greater)</title>
          <description>Will evaluate the incidence of hemorrhagic events (World Health Organization grade 2 or greater).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeds (World Health Organization Grade 3 or 4)</title>
        <description>Will evaluate the major bleeds (World Health Organization grade 3 or 4).</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeds (World Health Organization Grade 3 or 4)</title>
          <description>Will evaluate the major bleeds (World Health Organization grade 3 or 4).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Platelet Transfusions Per Patient During the Study Period</title>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Platelet Transfusions Per Patient During the Study Period</title>
          <units>platelet transfusions</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Days on Which Subjects Are Transfused (or Transfusion Are Not Given)</title>
        <description>The frequency with which transfusions are given despite a platelet count above the determined threshold will be documented, as will the frequency with which transfusions are not administered within 24 hours after a platelet count below the determined threshold.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Days on Which Subjects Are Transfused (or Transfusion Are Not Given)</title>
          <description>The frequency with which transfusions are given despite a platelet count above the determined threshold will be documented, as will the frequency with which transfusions are not administered within 24 hours after a platelet count below the determined threshold.</description>
          <units>percentage of study days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Transfusion Related Complications</title>
        <description>Total number of transfusion reactions, patients experiencing alloimmunization and volume overload will be reported.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Transfusion Related Complications</title>
          <description>Total number of transfusion reactions, patients experiencing alloimmunization and volume overload will be reported.</description>
          <units>Platelet transfusion complication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progressive or New Arterial Thromboembolism</title>
        <description>Will evaluate the progression or new arterial thromboembolism by either documented acute electrocardiographic changes compatible with myocardial injury and/or serum biochemical changes diagnostic of myocardial infarction, or documented imaging (computed tomography or magnetic resonance imaging) changes compatible with infarct due to embolism in the presence of a new neurological deficit, or imaging demonstrated intraluminal filling defects in an arterial distribution accompanied by symptoms of acute ischemia (acute onset pain, pallor, loss of pulses or other end-organ damage).</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Progressive or New Arterial Thromboembolism</title>
          <description>Will evaluate the progression or new arterial thromboembolism by either documented acute electrocardiographic changes compatible with myocardial injury and/or serum biochemical changes diagnostic of myocardial infarction, or documented imaging (computed tomography or magnetic resonance imaging) changes compatible with infarct due to embolism in the presence of a new neurological deficit, or imaging demonstrated intraluminal filling defects in an arterial distribution accompanied by symptoms of acute ischemia (acute onset pain, pallor, loss of pulses or other end-organ damage).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progressive or New Venous Thromboembolic</title>
        <description>Will evaluate the progressive or new venous thromboembolic. Will require imaging confirmation, defined as intraluminal filling defect(s) on contrast-enhanced computed tomography or incompressible venous segment(s) on ultrasonography.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group I (Lower Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Group II (Higher Dose Platelet Transfusion)</title>
            <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Progressive or New Venous Thromboembolic</title>
          <description>Will evaluate the progressive or new venous thromboembolic. Will require imaging confirmation, defined as intraluminal filling defect(s) on contrast-enhanced computed tomography or incompressible venous segment(s) on ultrasonography.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On study time (varied between subjects)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group I (Lower Dose Platelet Transfusion)</title>
          <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo lower dose platelet transfusion</description>
        </group>
        <group group_id="E2">
          <title>Group II (Higher Dose Platelet Transfusion)</title>
          <description>Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to &gt; 50 x 10^9 for 3 consecutive days in the absence of transfusions.
Platelet Transfusion: Undergo higher dose platelet transfusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>mucositis</sub_title>
                <description>Related to chemotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>transaminitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Bethany Samuelson Bannow</name_or_title>
      <organization>FHCRC</organization>
      <phone>5034949925</phone>
      <email>samuelsb@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

